Chromosome 17p deletion

Summary

Chromosome 17p deletion (MONDO:0022754) is a disease and 2 clinical trials. Top therapeutic interventions include daratumumab. A subtype of partial deletion of chromosome 17 — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	chromosome 17p deletion
Mondo ID	MONDO:0022754
MeSH	C538045
Orphanet	261965
ICD-11	527787991
NCIT	C36499
UMLS	C5679671
MedGen	1842221
GARD	0020817
Is cancer (heuristic)	no

Also known as: 17p deletion · 17p monosomy · 17p- syndrome · chromosome 17p deletion · chromosome 17p deletion syndrome · deletion 17p · deletion 17p syndrome · interstitial deletion 17p · monosomy 17p · partial deletion of chromosome 17p · partial deletion of the short arm of chromosome 17 · partial monosomy 17p · partial monosomy of chromosome 17p · partial monosomy of the short arm of chromosome 17 · partial monosomy of the short arm of chromosome type 17

Disease family

An umbrella term covering 4 Mondo subtypes.

Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › chromosomal disorder › syndrome caused by partial chromosomal deletion › partial deletion of chromosome 17 › chromosome 17p deletion

Related subtypes (1): partial deletion of the long arm of chromosome 17

Subtypes (4): hereditary neuropathy with liability to pressure palsies, Miller-Dieker lissencephaly syndrome, chromosome 17p13.1 deletion syndrome, distal 17p13.3 microdeletion syndrome

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04124497	PHASE2	ACTIVE_NOT_RECRUITING	A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma Patients
NCT01889186	PHASE2	COMPLETED	A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DARATUMUMAB	4	1